Study of Retinal and Vascular Features by Optical Coherence Tomography and Optical Coherence Tomography Angiography After Intravitreal Injections of Bevacizumab in Exudative Age-related Macular Degeneration
Overview
- Phase
- Not Applicable
- Intervention
- Bevacizumab Injection
- Conditions
- Exudative Age-related Macular Degeneration
- Sponsor
- Federico II University
- Enrollment
- 38
- Locations
- 1
- Primary Endpoint
- Study of retinal structural features in exudative age-related macular degeneration after intravitreal injections of Bevacizumab
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
This study evaluates the retinal and vascular features in patients with macular degeneration under the effects of Bevacizumab intravitreal injections using optical coherence tomography and optical coherence tomography angiography.
Detailed Description
Bevacizumab is a vascular endothelial growth factor antagonist represent an efficacy treatment for exudative age-related macular degeneration acting on vascular hyperpermeability. The optical coherence tomography and optical coherence tomography angiography represent novel and non-invasive diagnostic techniques that allow a detailed and quantitative analysis of retinal and vascular features. The study evaluates the changes in optical coherence tomography and optical coherence tomography angiography parameters at baseline and after three monthly injections of Bevacizumab in exudative AMD.
Investigators
Gilda Cennamo
Gilda Cennamo
Federico II University
Eligibility Criteria
Inclusion Criteria
- •age older than 50 years, diagnosis of exudative age-related macular degeneration, treatment-naïve with Bevacizumab for exudative age-related macular degeneration.
Exclusion Criteria
- •age younger than 50 years, diagnosis of exudative macular degeneration due to other causes, previous treatments before Bevacizumab for exudative age-related macular degeneration.
Arms & Interventions
Patients receiving Bevacizumab
Bevacizumab, intravitreal injection, three monthly, dosage: 1.25 mg/0.05 mL.
Intervention: Bevacizumab Injection
Outcomes
Primary Outcomes
Study of retinal structural features in exudative age-related macular degeneration after intravitreal injections of Bevacizumab
Time Frame: three months
The effectiveness of Bevacizumab injections for treating exudative age-related macular degeneration using optical coherence tomography. The parameters analyzed by optical coherence tomography: Central Macular Thickness and Subfoveal Choroidal thickness (microns).
Study of retinal vascular features in exudative age-related macular degeneration after intravitreal injections of Bevacizumab
Time Frame: three months
The effectiveness of Bevacizumab injections for treating exudative age-related macular degeneration using optical coherence tomography angiography. The parameters analyzed by optical coherence tomography angiography were: retinal and choriocapillaris vessel density (%).